… : "Our first quarter results reflect our … pharmacy-led operating model." Overview of First Quarter Results WBA first quarter … all business segments. First quarter operating loss was … and equipment (capital expenditures), plus acquisition related …

… (WBA 27.82%) Q1 2025 Earnings Call Jan … now cover U.S. pharmacy. Pharmacy comp sales increased 12 … benefited from decreased capital expenditures and higher adjusted operating … outperformance of the first quarter, particularly on the pharmacy side, that, …

… of PWS in the first quarter of 2025. Rhythm plans … hyperphagia or address low energy expenditure. Bivamelagon (LB54640) Rhythm … MC4R agonist, in the first quarter of 2025. The Company … and Corporate Communications Rhythm Pharmaceuticals, Inc. 857-264- …

– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways – – Data from expansion arms in Phase 1/1b clinical trial …

… safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single … milestones from Qilu Pharmaceutical, its strategic partner … its operations through the first quarter of 2028. This … operating expenses and capital expenditures. A more complete …

… Development at Jazz Pharmaceuticals (formally GW Pharmaceuticals) where he was … clinical trial in the first quarter of 2025 to assess … is anticipated in the first quarter of 2026. About … and development and capital expenditures. Forward-looking statements are …

… are anticipated in the first quarter of 2025. In addition … in Q1 2025, including data on safety, pharmacokinetics, VAV1 … planned operations and capital expenditures into 2028. J.P … degradation, and key downstream pharmacodynamic markers, submitting an …

… Phase 3 trial in the first quarter and to initiate two additional … , Chief Commercial Officer, at Lexicon Pharmaceuticals. Prior to Lexicon, Mr. Santini … unforeseeable operating expenses and capital expenditure requirements, and other important factors …

… expected to initiate in Q1 2025, with top- … and tolerability, and pharmacokinetics and pharmacodynamics consistent with sustained … factors; risks inherent in pharmaceutical research and development, … possibility of unexpected cash expenditures; our ability to …

… quarter was a large multinational pharmaceutical and healthcare company that … flows from investing activities Capital expenditures   (18,465 )   (22,301 ) … Quarter 2025 (in millions) Q1 25 Q2 25 Q3 25 … $21.1 $54.7         Capital expenditures (6.1) (6.2) (6 …